NCT02691767View on ClinicalTrials.gov

Study to Evaluate the Safety and Efficacy of Pazopanib, in Subject With Refractory Solid Tumors

NACompletedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

January 16, 2018

Study Completion Date

February 13, 2020

Conditions
Refractory Solid Tumors
Interventions
DRUG

pazopanib

Trial Locations (1)

135-710

Samsung Medical Center, Seoul

All Listed Sponsors
lead

Samsung Medical Center

OTHER

NCT02691767 - Study to Evaluate the Safety and Efficacy of Pazopanib, in Subject With Refractory Solid Tumors | Biotech Hunter | Biotech Hunter